​

BridgeBio Pharma Ownership | Who Owns BridgeBio Pharma?

OverviewForecastRevenueFinancialsChartTranscripts

BridgeBio Pharma Ownership Summary

BridgeBio Pharma is owned by 99.09% institutional investors, 4.77% insiders. Viking global investors lp is the largest institutional shareholder, holding 9.74% of BBIO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in BridgeBio Pharma shares.

BBIO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBridgeBio Pharma99.09%4.77%-3.85%
SectorHealthcare Stocks 492.67%11.09%-403.76%
IndustryBiotech Stocks 295.31%11.22%-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Viking global investors lp18.56M9.74%$801.22M
Vanguard group16.83M8.83%$874.26M
Blackrock funding, inc. /de14.41M7.56%$748.52M
Kohlberg kravis roberts13.26M6.96%$572.61M
Blackrock12.45M6.64%$315.31M
Farallon capital management7.90M4.15%$341.12M
State street6.18M3.28%$169.65M
Aisling capital management lp6.09M3.20%$316.29M
Janus henderson group4.91M2.60%$134.67M
Capital research global investors3.99M2.09%$172.21M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aisling capital management lp6.09M69.29%$316.29M
Kohlberg kravis roberts13.26M11.83%$572.61M
Frazier life sciences management3.80M6.56%$164.10M
Cutter capital management, lp560.34K6.30%$15.38M
Lion point capital, lp40.30K5.79%$1.11M
Monashee investment management200.00K5.18%$10.39M
Cormorant asset management, lp1.60M5.15%$69.09M
Prosight management, lp472.69K4.98%$20.41M
Superstring capital management lp96.77K4.95%$4.18M
Exome asset management155.53K4.25%$6.72M

Top Buyers

HolderShares% AssetsChange
Farallon capital management7.90M1.47%2.17M
Blackrock12.45M0.01%1.98M
Woodline partners lp2.21M0.41%1.26M
Norges bank1.07M0.00%1.07M
Balyasny asset management1.64M0.11%841.54K

Top Sellers

HolderShares% AssetsChange
Kohlberg kravis roberts13.26M11.83%-6.00M
Viking global investors lp18.56M2.32%-3.50M
Deep track capital, lp900.00K1.25%-1.90M
Perceptive advisors---1.22M
Paradigm biocapital advisors lp---1.09M

New Positions

HolderShares% AssetsChangeValue
Norges bank1.07M0.00%1.07M$29.24M
Gw&k investment management598.24K0.27%598.24K$31.07M
Candriam s.c.a.148.99K0.04%148.99K$7.74M
Winton group89.31K0.20%89.31K$3.86M
Td asset management88.95K0.00%88.95K$4.62B

Sold Out

HolderChange
Weiss asset management lp-1.00
Financial gravity asset management-3.00
Creekmur asset management-3.00
Twin peaks wealth advisors-6.00
Rakuten securities-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202539213.29%188,775,9601.99%991.05%22614.14%10932.93%
Mar 31, 202534412.05%185,144,5074.79%971.11%19624.05%825.13%
Dec 31, 20243048.57%172,882,4320.83%911.11%1556.90%781.30%
Sep 30, 2024278-2.11%171,231,529-1.98%901.05%147-3.29%742.78%
Jun 30, 20242841.43%174,683,4282.52%931.02%15211.76%72-15.29%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv5.40M2.83%-130.43K
Vanguard US Total Market Shares ETF4.53M2.38%3.92K
Vanguard Small Cap Index4.15M2.17%-28.15K
iShares Russell 2000 ETF3.77M1.97%-
SPDR® S&P Biotech ETF2.40M1.26%5.36K
Vanguard Small Cap Growth Index Inv2.34M1.22%-6.35K
American Funds SMALLCAP World A2.07M1.09%-596.87K
Janus Henderson Global Life Sciences1.62M0.85%573.25K
Janus Henderson Global Life Sciences D1.62M0.85%28.25K
Vanguard Institutional Extnd Mkt Idx Tr1.59M0.83%-695.01K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 07, 2025Kumar Neil Chief Executive OfficerSell$763.76K
Nov 06, 2025Kumar Neil Chief Executive OfficerSell$6.44K
Nov 06, 2025Kumar Neil Chief Executive OfficerSell$465.42K
Nov 06, 2025Kumar Neil Chief Executive OfficerSell$791.17K
Nov 07, 2025Kumar Neil Chief Executive OfficerSell$452.16K

Insider Transactions Trends

DateBuySell
2025 Q4-13
2025 Q3-35
2025 Q2-16
2025 Q1-15
2024 Q4-3

BBIO Ownership FAQ

Who Owns BridgeBio Pharma?

BridgeBio Pharma shareholders are primarily institutional investors at 99.09%, followed by 4.77% insiders and -3.86% retail investors. The average institutional ownership in BridgeBio Pharma's industry, Biotech Stocks , is 295.31%, which BridgeBio Pharma falls below.

Who owns the most shares of BridgeBio Pharma?

BridgeBio Pharma’s largest shareholders are Viking global investors lp (18.56M shares, 9.74%), Vanguard group (16.83M shares, 8.83%), and Blackrock funding, inc. /de (14.41M shares, 7.56%). Together, they hold 26.14% of BridgeBio Pharma’s total shares outstanding.

Does Blackrock own BridgeBio Pharma?

Yes, BlackRock owns 6.64% of BridgeBio Pharma, totaling 12.45M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 315.31M$. In the last quarter, BlackRock increased its holdings by 1.98M shares, a 18.93% change.

Who is BridgeBio Pharma’s biggest shareholder by percentage of total assets invested?

Aisling capital management lp is BridgeBio Pharma’s biggest shareholder by percentage of total assets invested, with 69.29% of its assets in 6.09M BridgeBio Pharma shares, valued at 316.29M$.

Who is the top mutual fund holder of BridgeBio Pharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of BridgeBio Pharma shares, with 2.83% of its total shares outstanding invested in 5.4M BridgeBio Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools